Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 10 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11679143

    FGF21 variant, fusion protein and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  2. US 11679159

    Compositions for transfecting resistant cell types

    Precision Nanosystems ULC · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  3. US 11666547

    Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)

    Northwestern University · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  4. US 11666602

    Treatment of pulmonary arterial hypertension with mesenchymal stem cells

    United Therapeutics Corporation · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  5. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Iovance Biotherapeutics, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  6. US 11661601

    Methods for modulating FMR1 expression

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 30, 2023 · Expires May 25, 2043

    granted
  7. US 11649207

    Formulations of T-type calcium channel modulators and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  8. US 11642390

    Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  9. US 11639504

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  10. US 11638708

    Method of treatment of aggression

    Supernus Pharmaceuticals, Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  11. US 11634711

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  12. US 11633483

    Modulators of PCSK9 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  13. US 11629146

    Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity

    PRAXIS PRECISION MEDICINES, INC. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  14. US 11629349

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  15. WO 2023054310

    ENSEMBLE DE PERFUSION GOUTTE-À-GOUTTE INTRAVEINEUX POURVU D'UN FILTRE DE PERFUSION À ÉVENT D'AIR

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Apr 6, 2023 · Expires Apr 1, 2043

    granted
  16. US 11613752

    Compositions and methods for modulating PKK expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  17. US 11607412

    Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

    TENAX THERAPEUTICS, INC. · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  18. US 11602559

    HIV-1 Env fusion peptide immunogens and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  19. CA 3230406

    UTILISATION DE MICRO-ARN POUR LA REGULATION NEGATIVE DE L'EXPRESSION DE TRANSGENES CYTOTOXIQUES PAR LE VIRUS DE LA VACCINE ANKARA MODIFIE (MVA)

    BAVARIAN NORDIC AS [DK] · Granted Mar 9, 2023 · Expires Mar 4, 2043

    granted
  20. US 11596671

    Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  21. US 11590179

    Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection

    PrecisionBiotics Group Limited · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  22. US 11583548

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  23. US 11572575

    Compositions for transfecting resistant cell types

    Precision Nanosystems ULC · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted
  24. US 11572413

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted